Ionic Materials

Organix performs contract research and development for organic and medicinal chemistry and biotechnology applications. The company s capabilities include custom synthesis of organic molecules; optimization of existing synthetic methods; structure activity relationship studies to discover new molecules and optimize lead compounds; joint projects to discover and synthesize new molecular entities designed for specific functions; and characterization of components of complex organic mixtures. Organix is licensed by the United States Drug Enforcement Agency and the Commonwealth of Massachusetts to conduct research and manufacturing processes of controlled substances in schedules one to four. Its staff of scientists has been published in numerous scientific journals. The company was founded in 1986 and is based in Woburn, Mass.

CellMosaic, Inc. is a biotechnology company located in Woburn, Massachusetts, specializing in Antibody Drug Conjugate (ADC) and other drug conjugate solutions. They offer a wide range of products and services including ADC kits, custom bioconjugation, and bioconjugate drug development, catering to both research and manufacturing needs. In addition to their product offerings, CellMosaic also provides comprehensive analysis and purification services, employing advanced technologies such as AqueaTether and photocrosslinking processes. Their commitment to innovation is reflected in their diverse portfolio, which includes reagents, assay kits, and custom services for various bioconjugation applications. Generated from the website

Cyta Therapeutics, Inc. is an early-stage life sciences company based in Woburn, MA, focused on developing proprietary products for the treatment of obesity and related metabolic conditions. The company's lead development program, Cyta001, utilizes a novel polymer-based nanogel technology called IntelliGel to deliver a potent thyromimetic drug, targeting liver cells to reverse body weight gain and improve metabolic parameters. Founded on innovative research from the University of Massachusetts Amherst, Cyta aims to address the global obesity epidemic affecting over 650 million people. With a strong team and a commitment to advancing its therapeutic pipeline, Cyta Therapeutics seeks partnerships to enhance its drug delivery solutions and improve therapeutic outcomes for chronic medical conditions linked to obesity. Generated from the website